Daré Bioscience shareholders approve 1.5 million-share increase to 2022 stock incentive plan at annual meeting

• Dare Bioscience held its annual stockholder meeting on June 11, 2026.
• Stockholders ratified Haskell & White as independent auditor for the fiscal year ending Dec. 31, 2026.
• Stockholders authorized potential future issuance of common shares under the existing equity line with Lincoln Park Capital Fund.
• Stockholders adopted an amendment to the 2022 Stock Incentive Plan, increasing shares available for issuance by 1.5 million; the board’s prior approval becomes effective.
• Stockholders also authorized adjournment proposals tied to the equity-line share issuance and the plan amendment; neither adjournment was needed.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dare Bioscience Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001401914-26-000032), on June 12, 2026, and is solely responsible for the information contained therein.